Alberta Health services addresses concerns regarding the use of imported acetaminophen from Turkey during the previous winter. Health Canada approved its import, emphasizing no patients, including infants in neonatal intensive care, suffered injuries due to its usage.
The decision to discontinue the imported pain medication in NICUs stemmed from frontline staff identifying a higher risk of clogging feeding tubes due to increased viscosity. While termed “adverse reactions” these incidents did not result in injuries.
In healthcare instances such as the need for an unnecessary procedure, like replacing a feeding tube, are classified as adverse events. Misinterpretation of product packaging and labeling also falls under this category.
The Atabay product was used for approximately two months in AHS sites before reverting to the usual medication.
In early 2023, Canada faces challenges in the supply of children’s analgesics, prompting proactive decisions to prevent a complete shortfall. Atabay, with Good Manufacturing Practice certification, became a crucial solution, ensuring a stable supply amid global shortages.
Atabay’s certification in the USA, Japan, Australia, and the European Union, along with its exclusive role as acetaminophen manufacturer in key regions, provided AHS with long-term assurance for their stick during a period of heightened demand and shortages. AHS reaffirms its commitment to patient safety and transparent communication in healthcare decisions.
